Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

761 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
NCCN Practice Guidelines for Chronic Myelogenous Leukemia.
Berman E, Clift RA, Copelan EA, Emanuel PD, Erba HP, Glenn MJ, Greenberg PL, Jones RJ, O'Brien S, Saba HI, Schilder R, Snyder DS, Soiffer RJ, Tallman MS, Wetzler M, Ravandi-Kashani F, Kantarjian H, Talpaz M; National Comprehensive Cancer Network. Berman E, et al. Among authors: jones rj. Oncology (Williston Park). 2000 Nov;14(11A):229-40. Oncology (Williston Park). 2000. PMID: 11195415 No abstract available.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh MM, Mishra A, Muffly L, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson KJ, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal AM, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: jones rj. Blood. 2025 Jan 7:blood.2024025154. doi: 10.1182/blood.2024025154. Online ahead of print. Blood. 2025. PMID: 39775763
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.
Holtan SG, Bolaños-Meade J, Al Malki MM, Wu J, Kitko CL, Reshef R, Rezvani AR, Shaffer BC, Solh MM, Yao JM, Runaas L, Elmariah H, Larkin KT, El Jurdi N, Gooptu M, Loren AW, Hall AC, Alousi AM, Jamy O, Clark W, Kean L, Bhatt AS, Perales MA, Applegate K, Efebera YA, Leifer E, Jones RJ, Horowitz MM, Mattila D, Saber W, Hamadani M, Martens MJ. Holtan SG, et al. Among authors: jones rj. J Clin Oncol. 2025 Jan 3:JCO2400921. doi: 10.1200/JCO.24.00921. Online ahead of print. J Clin Oncol. 2025. PMID: 39752608
Improved Overall Survival with Checkpoint Inhibition and Allogeneic Transplantation in Relapsed Hodgkin Lymphoma.
Tabbara N, Zahurak ML, Sterling C, Trutzer IM, Jedrych J, Swinnen LJ, Fuchs EJ, Bolaños-Meade J, Wagner-Johnston ND, Jones RJ, Ambinder RF, Varadhan R, Paul S. Tabbara N, et al. Among authors: jones rj. Blood Adv. 2024 Dec 18:bloodadvances.2024015048. doi: 10.1182/bloodadvances.2024015048. Online ahead of print. Blood Adv. 2024. PMID: 39693511
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study.
Azad AA, Fizazi K, Matsubara N, Saad F, De Giorgi U, Joung JY, Fong PCC, Jones RJ, Zschäbitz S, Oldenburg J, Shore ND, Dunshee C, Carles J, Fay AP, Lin X, DeAnnuntis L, Di Santo N, Zielinski MA, Agarwal N. Azad AA, et al. Among authors: jones rj. Eur J Cancer. 2024 Dec;213:115078. doi: 10.1016/j.ejca.2024.115078. Epub 2024 Oct 20. Eur J Cancer. 2024. PMID: 39486165 Free article. Clinical Trial.
Physiotherapy: the history behind the word.
Ruscoe GA, Schiller S, Jones RJ, MacDonald CW, McGrath RL. Ruscoe GA, et al. Among authors: jones rj. Physiother Theory Pract. 2024 Nov;40(11):2469-2471. doi: 10.1080/09593985.2024.2414548. Epub 2024 Oct 23. Physiother Theory Pract. 2024. PMID: 39440425 No abstract available.
StratosPHere 2: study protocol for a response-adaptive randomised placebo-controlled phase II trial to evaluate hydroxychloroquine and phenylbutyrate in pulmonary arterial hypertension caused by mutations in BMPR2.
Deliu N, Das R, May A, Newman J, Steele J, Duckworth M, Jones RJ, Wilkins MR, Toshner MR, Villar SS. Deliu N, et al. Among authors: jones rj. Trials. 2024 Oct 15;25(1):680. doi: 10.1186/s13063-024-08485-z. Trials. 2024. PMID: 39407331 Free PMC article.
761 results